
President Obama’s settled the score on this one: It’s precision medicine. Not personalized medicine.
The life sciences community has been throwing around both terms, but there’s actually a keen distinction between the two.

President Obama’s settled the score on this one: It’s precision medicine. Not personalized medicine.
The life sciences community has been throwing around both terms, but there’s actually a keen distinction between the two.

Biotechnology companies in the Washington region attracted less money from investors in 2014 than any other year since 1999, recent data show, even as the sector saw a significant increase in venture capital dollars in other parts of the country.
Local industry observers aren’t sounding alarms just yet. They say one down year, no matter how down it may be, doesn’t necessarily mean the region has fallen out of favor with life sciences investors.

DreamIt Health Baltimore is leasing 4,500 square feet of space at Power Plant Live!, a space Executive Director Jason Hardebeck envisions as a future hub for health care technology startups.
DreamIt’s lease runs through May when the business accelerator wraps up its 16-week program. Hardebeck said he has been in talks with Cordish Cos., the property’s developer, to re-purpose the office as a co-working space for graduate companies once the accelerator program ends. DreamIt would also maintain a presence there.

February 10th at 2pm ET
Every Phase II NIH SBIR/STTR application requires a commercialization plan, which essentially describes how the company plans bring its innovative technology to market. In this Hangout, we will discuss the key elements of a successful commercialization plan.

Position Summary
GenVec is seeking a highly motivated professional who is able to make strong contributions in supporting all business and corporate development activities. The successful candidate will work directly with the Chief Executive Officer and will interact extensively with the scientific, legal, and financial personnel of the company to review and evaluate the scientific and commercial aspects of potential transactions. The Business Development Analyst will be responsible for supporting a portfolio of business development projects which address in-licensing, out-licensing, and acquisition opportunities for GenVec.

Roche has become the latest pharmaceutical company to join the connected health party at Qualcomm Life — in this case to do remote patient monitoring. The goal of the strategic collaboration is to generate big data insights on patients’ condition to reduce complications from chronic conditions, according to a company statement.

Vaccinations are obviously a hot topic for debate – it’s exhausting. But with the recent measles outbreak at Disneyland, it’s even more clear that this is getting just a bit ridiculous.
Parents really want to know who’s vaccinated and who’s not. And families in some states should be a little more concerned than others, according to numbers from the Centers for Disease Control.

Qiagen NV (NASDAQ: QGEN ) solutions are used every day by healthcare providers to analyze patient DNA and RNA in order to guide treatment and by researchers pursuing next generation medicine. The opportunity for Qiagen to help the industry deliver the right drug to the right patient at the right dose at the right time is big, but a significant drop-off in revenue from a legacy product meant that potential didn’t translate into significant sales growth last year.

Benjamin H. Wu has been named the new Deputy Secretary of the Maryland Department of Business and Economic Development, Governor Larry Hogan and DBED Secretary Mike Gill announced today.
A former DBED employee, Wu is among the first Cabinet deputies to be named to the Hogan administration. He will act as Chief Operating Officer, responsible for overseeing the Department’s charge of attracting companies to the State, as well as working with in-state companies to help them expand and add jobs, while connecting them to partners and resources.

LSN researchers recently decided to take a deep dive into interviews we have held with venture philanthropy groups from around the world to see what the future likely has in store. After analyzing data gathered over the past three years from more than 150 investors, we uncovered a few notable trends.